drugset / Trial / NCT05480436
Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population
Phase 4
Unknown
1200 enrolled
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd. · collabChengdu Institute of Biological Products Co.,Ltd. · collabGuizhou Center for Disease Control and Prevention · collabHunan Provincial Center for Disease Control and Prevention · collabShanghai Institute Of Biological Products · collabSichuan Center for Disease Control and Prevention · collabXiangya Hospital of Central South University · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
Evaluation of immunogenicity and safety of inactivated COVID-19 vaccine (BBIBP-Corv) coadministered with PPV23 and IIV4 in hemodialysis population.
Timeline
- Start
- 2022-08-05
- Primary completion
- 2023-01-30
- Completion
- 2023-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BBIBP-CorV | Vaccine | — | — |
| Subject | Influenza Virus Vaccine | Vaccine | — | — |
| Comparator | Pneumovax 23 | Vaccine | — | — |